EC Number   |
Protein Variants |
Reference |
|---|
   2.7.11.22 | C67W |
mutation renders the resulting mutant protein p80cdc25-independent, while neither Leu, Ile nor Val has this effect |
491462 |
| 2.7.11.22 | D144N |
defective in its kinase activity, weakly increases glucocorticoid receptor-induced transcriptional activity |
681935 |
| 2.7.11.22 | D144N |
dominant-negative CDK5 mutant, results in a loss of motility of the cells through effects on the cytoskeleton, which correlates with dramatically lower invasive potential, leads to 79% reduction in the number of lung metastases per milligram of primary xenograft tumors |
679026 |
| 2.7.11.22 | D146N |
mutant forms kinase-inactive complexes |
682384 |
| 2.7.11.22 | D146N |
overexpression results in elongated cells after cell division is arrested, shows phosphorylation of T161 |
682384 |
| 2.7.11.22 | D146N/T161A |
retains a dominant-negative effect on cellular growth, shows phosphorylation of T161 |
682384 |
| 2.7.11.22 | F143L |
4-10fold increase in Pfmrk activity, significant kinase activity in the absence of either cyclin or PfMAT1 |
681816 |
| 2.7.11.22 | F91G |
replacement of wild-type Cdk7 with a version sensitive to bulky ATP analogs in human cancer cells, designated Cdk7as |
681881 |
| 2.7.11.22 | K146A |
mutant is unable to bind ATP |
682579 |
| 2.7.11.22 | K146A |
mutation of the invariant lysine in subdomain II critical for ATP binding |
682579 |
